Cadila Healthcare has rallied 5% to Rs 454, also its record high on the BSE in early morning trade, after reporting a strong 40% year on year (YoY) growth in consolidated net profit at Rs 391 crore for the quarter ended September 30, 2015 (Q2). The pharmaceutical company had profit of Rs 278 crore in a year ago quarter.
Its total income has increased by 17% at Rs 2,460 crore on YoY basis.
Earnings before interest, tax, depreciation and amortization (EBITDA) margin improved to 25.3% in September quarter from 19.97% in the corresponding quarter of previous fiscal.
During the quarter, the company’s business in US posted sales of Rs 1,004 crore registering a growth of 25%. The company received approval for one new product from the USFDA and two products were launched in the US market, Cadila Healthcare said in a release.
At 09:21 am, the stock was up 2.6% at Rs 443 on the BSE. A combined 579,730 shares changed hands on the counter on the BSE and NSE.